UBXN8

Across TCGA pan-cancer cohorts, UBXN8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBXN8 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher UBXN8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBXN8 expression acts as an unfavorable survival marker.

ACC, UCEC, and LUSC are the cancer types where UBXN8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	II,III,IV	0.280	0.742	.037	6	view →
SKCM	DFS	Median	All	0.267	0.623	.008	6	view →
BRCA	OS	Median	All	0.181	0.579	.048	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBXN8–ACC (OS)

Open the ACC breakdown →